2-Isothiazolidinebutanoic acid, 1,1-dioxide | 1016696-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2-Isothiazolidinebutanoic acid, 1,1-dioxide
• 英文别名: 4-(1,1-dioxo-1,2-thiazolidin-2-yl)butanoic acid
• CAS: 1016696-75-5
• 化学式: C₇H₁₃NO₄S
• 分子量: 207.25
• InChiKey: MMMPPBNBFMAYAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：Biediger Ronald J.

  公开号：US20130236434A1

  公开（公告）日：2013-09-12

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体的结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素选自α4β1、α5β1、α4β7、αvβ3和αLβ2群，然后将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；使用这种激动剂治疗表达整合素的细胞以增强结合的方法；以及包括将激动剂处理的细胞或激动剂化合物给哺乳动物的治疗方法。
• AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
  申请人：TEXAS HEART INSTITUTE

  公开号：US20150368234A1

  公开（公告）日：2015-12-24

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法包括在体外用整合素激动剂处理表达整合素的细胞，其中整合素被选择自α4β1、α5β1、α4β7、αvβ3和αLβ2组成的群体中的一种，并将处理后的细胞与整合素结合配体接触；具有一般式I的整合素激动剂化合物；用这样的激动剂处理表达整合素的细胞以增强结合的方法；以及包括向哺乳动物施用经激动剂处理的细胞或激动剂化合物的治疗方法。
• Agonists that enhanced binding of integrin-expressing cells to integrin receptors
  申请人：TEXAS HEART INSTITUTE

  公开号：US10035784B2

  公开（公告）日：2018-07-31

  A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

  一种增强细胞与整合素结合配体结合的方法，包括在体外用整合素的激动剂处理表达整合素的细胞，其中整合素选自由α4β1、α5β1、α4β7、αvβ3和αLβ2组成的组，并使处理过的细胞与整合素结合配体接触；具有通式Ⅰ的整合素激动剂化合物；用这种激动剂处理整合素表达细胞以增强结合的方法；以及治疗方法，包括给哺乳动物施用激动剂处理过的细胞或激动剂化合物。
• Agonists that enhance binding of integrin-expressing cells to integrin receptors
  申请人：Texas Heart Institute

  公开号：EP2881392B1

  公开（公告）日：2018-06-06
• US9512109B2
  申请人：——

  公开号：US9512109B2

  公开（公告）日：2016-12-06